Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia
Status:
Terminated
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in
different ways to stop the growth of cancer cells, either by killing the cells or by stopping
them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in
different ways. Some find cancer cells and kill them or carry cancer-killing substances to
them. Others interfere with the ability of cancer cells to grow and spread. Giving
fludarabine and cyclophosphamide together with rituximab may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving fludarabine and cyclophosphamide
together with rituximab works in treating patients with B-cell prolymphocytic leukemia.